 | The topic of this article may not meet Misplaced Pages's notability guidelines for companies and organizations. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources: "Acura Pharmaceuticals" – news · newspapers · books · scholar · JSTOR (February 2014) (Learn how and when to remove this message) |
| Company type | Public |
|---|---|
| Traded as | Nasdaq: ACUR |
| Industry | Pharmaceutical industry |
| Founded | 1935; 89 years ago (1935) |
| Headquarters | Palatine, Illinois |
| Products | Pharmaceuticals |
| Revenue |  US$ .75 million (2015) |
| Website | acurapharm |
Acura Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of deterrents to medication abuse and misuse. As of 2012, the company had several opioid products under development, which would use "Aversion Technology". As of 2014, it was a publicly traded company, listed on NASDAQ under the symbol "ACUR".
History
In 2013, the Company settled Oxecta patent litigation with Impax Laboratories (IPXL) and Par Pharmaceutical.
License agreements
The company has an agreement to license, develop and commercialize opioid analgesic products with King Pharmaceuticals.
Product adoptions
In 2013, multiple retailers – including Kroger and Fruth Pharmacy – stocked Acura's product Nexafed.
References
- "ACURA PHARMACEUTICALS, INC" (PDF). EDGAR Online. Form 10-K, 1996. Acura Pharmaceuticals. March 31, 1997. Retrieved February 15, 2014.
- "Acura Pharmaceuticals Financial Statements". United States Securities and Exchange Commission.
- "Acura Pharmaceuticals Announces Second Quarter 2020 Financial Results". AP NEWS. 2020-08-14. Retrieved 2021-07-22.
- "Acura Pharmaceuticals, Inc". Google Finance. 266634. Archived from the original on 10 May 2014. Retrieved February 15, 2014.
{{cite web}}: CS1 maint: bot: original URL status unknown (link) - "Acura Pharmaceuticals Inc Announces Settlement of Oxecta Patent Litigation With Par Pharmaceutical and Impax Laboratories Inc". Reuters. Reuters. October 9, 2013. Archived from the original on February 15, 2014.
- "ACURA PHARMACEUTICALS INC (ACUR) Company Profile & Facts - Yahoo Finance".
- Olsavsky, Rebecca (February 4, 2014). "Kroger stocks meth-resistant drug". Herald-Star. Archived from the original on February 15, 2014. Retrieved February 15, 2014.
- "New Pseudoephedrine Drug Could Hop Back Over the Counter". PharmExec. 11 December 2012. Retrieved 2021-07-22.